2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Tania Jain, MBBS, sheds light on the mutations that confer worse prognosis in myelofibrosis.
Tania Jain, MBBS, assistant professor of oncology, Division of Hematological Malignancies and Stem Cell Transplantation, Johns Hopkins University, sheds light on the mutations that confer worse prognosis in myelofibrosis.
Patients with mutations in ASXL1, EZH2, SRSF2, IDH1/2, and U2AF1 have high-risk myelofibrosis, says Jain. These patients typically have decreased leukemia-free survival and overall survival, explains Jain.
As a result, patients who harbor these mutations may be considered for allogeneic stem cell transplant sooner in their disease course compared with patients without these mutations, concludes Jain.